Cargando…

The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold

Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize interferon signaling by binding host karyopherin α pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Adrianna P. P., Bornholdt, Zachary A., Liu, Tong, Abelson, Dafna M., Lee, David E., Li, Sheng, Woods, Virgil L., Saphire, Erica Ollmann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285596/
https://www.ncbi.nlm.nih.gov/pubmed/22383882
http://dx.doi.org/10.1371/journal.ppat.1002550
_version_ 1782224489501687808
author Zhang, Adrianna P. P.
Bornholdt, Zachary A.
Liu, Tong
Abelson, Dafna M.
Lee, David E.
Li, Sheng
Woods, Virgil L.
Saphire, Erica Ollmann
author_facet Zhang, Adrianna P. P.
Bornholdt, Zachary A.
Liu, Tong
Abelson, Dafna M.
Lee, David E.
Li, Sheng
Woods, Virgil L.
Saphire, Erica Ollmann
author_sort Zhang, Adrianna P. P.
collection PubMed
description Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize interferon signaling by binding host karyopherin α proteins, thereby preventing them from transporting the tyrosine-phosphorylated transcription factor STAT1 to the nucleus. Here, we report that VP24 binds STAT1 directly, suggesting that VP24 can suppress at least two distinct branches of the interferon pathway. Here, we also report the first crystal structures of VP24, derived from different species of ebolavirus that are pathogenic (Sudan) and nonpathogenic to humans (Reston). These structures reveal that VP24 has a novel, pyramidal fold. A site on a particular face of the pyramid exhibits reduced solvent exchange when in complex with STAT1. This site is above two highly conserved pockets in VP24 that contain key residues previously implicated in virulence. These crystal structures and accompanying biochemical analysis map differences between pathogenic and nonpathogenic viruses, offer templates for drug design, and provide the three-dimensional framework necessary for biological dissection of the many functions of VP24 in the virus life cycle.
format Online
Article
Text
id pubmed-3285596
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32855962012-03-01 The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold Zhang, Adrianna P. P. Bornholdt, Zachary A. Liu, Tong Abelson, Dafna M. Lee, David E. Li, Sheng Woods, Virgil L. Saphire, Erica Ollmann PLoS Pathog Research Article Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize interferon signaling by binding host karyopherin α proteins, thereby preventing them from transporting the tyrosine-phosphorylated transcription factor STAT1 to the nucleus. Here, we report that VP24 binds STAT1 directly, suggesting that VP24 can suppress at least two distinct branches of the interferon pathway. Here, we also report the first crystal structures of VP24, derived from different species of ebolavirus that are pathogenic (Sudan) and nonpathogenic to humans (Reston). These structures reveal that VP24 has a novel, pyramidal fold. A site on a particular face of the pyramid exhibits reduced solvent exchange when in complex with STAT1. This site is above two highly conserved pockets in VP24 that contain key residues previously implicated in virulence. These crystal structures and accompanying biochemical analysis map differences between pathogenic and nonpathogenic viruses, offer templates for drug design, and provide the three-dimensional framework necessary for biological dissection of the many functions of VP24 in the virus life cycle. Public Library of Science 2012-02-23 /pmc/articles/PMC3285596/ /pubmed/22383882 http://dx.doi.org/10.1371/journal.ppat.1002550 Text en Zhang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhang, Adrianna P. P.
Bornholdt, Zachary A.
Liu, Tong
Abelson, Dafna M.
Lee, David E.
Li, Sheng
Woods, Virgil L.
Saphire, Erica Ollmann
The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
title The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
title_full The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
title_fullStr The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
title_full_unstemmed The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
title_short The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
title_sort ebola virus interferon antagonist vp24 directly binds stat1 and has a novel, pyramidal fold
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285596/
https://www.ncbi.nlm.nih.gov/pubmed/22383882
http://dx.doi.org/10.1371/journal.ppat.1002550
work_keys_str_mv AT zhangadriannapp theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT bornholdtzacharya theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT liutong theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT abelsondafnam theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT leedavide theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT lisheng theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT woodsvirgill theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT saphireericaollmann theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT zhangadriannapp ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT bornholdtzacharya ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT liutong ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT abelsondafnam ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT leedavide ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT lisheng ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT woodsvirgill ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold
AT saphireericaollmann ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold